The review of the 2001 NHMRC/ASBT Clinical Practice Guidelines for the Use of Blood Components is being undertaken with funding and project management provided by the National Blood Authority (NBA) on behalf of all governments. The NBA has facilitated the formulation of a Steering Committee, Expert Working Group, and Clinical/Consumer Reference Groups.

The review will result in the production of six modules as part of a comprehensive, evidence-based, Patient Blood Management Guideline in three phases as follows:

• Phase 1:
  • Module 1 - Critical Bleeding/Massive Transfusion
  • Module 2 - Peri-operative
• Phase 2:
  • Module 3 - Medical
  • Module 4 - Intensive Care
• Phase 3:
  • Module 5 - Obstetric
  • Module 6 - Paediatric / Neonates

Each module of the Patient Blood Management Guideline will be subject to NHMRC approval, (including methodological and peer review) and an independent AGREE II assessment.

You can keep up to date with the development of the Blood Management Guideline via our Progress Updates or by registering for regular email updates.

The Critical Bleeding/Massive Transfusion module is now available on this website. Public consultation on the Perioperative module has closed and it will be considered for NHMRC approval at their October Council meeting.

Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg)

RFT 01/2012 - Review of the authorisation and clinical governance framework for intravenous immunoglobulin

AHMC Stewardship Statement

Blood Supply to Australians Oversea

New supply arrangements for IVIg